Cohen & Steers (CNS): Chairman Buys Millions—Time To Clip the Coupon or Clip Your Wings?
CNS shows mid-single-digit revenue growth, double-digit EPS growth, and a fresh $2.85M insider buy. Real-asset optionality, de-foamed multiple, TL;DR + FAQs.
CEO Buys Shares of CSX. Should You Board Or Stay Off-Track?
CEO buy signal, steady margins, and intermodal momentum—yet top line is flat-ish and valuation looks fair. Our fun + smart breakdown with TL;DR & FAQs.
CEO Bought Shares At Twice Today’s Price: Time To Buy Iridium Communications (IRDM)?
CEO bought at ~$37; shares now ~$19. We break down Iridium’s moat, IoT and PNT/D2D bets, valuation reset, and key risks—without the rocket emojis (ok, a few).
Insiders Had Bought Shares of Elanco Animal Health (ELAN); Turns Out They Were Right — And It May Only Be the Beginning!
Insiders bought millions of Elanco shares under $15 — and they were right. Now, with JP Morgan’s upgrade and revenues rising, this stock might be a hidden gem in the animal health world. 🐾
Six Months Ago, a Director Bought Sweetgreen (SG) at Twice the Price It Trades Today — Should You Indulge?
Sweetgreen’s stock has been chopped in half, insiders are under water, and institutions somehow own more shares than exist. But with AI-powered “Infinite Kitchens,” loyal customers, and a cult brand, could this be the comeback salad of the year—or another case of tossed expectations?
Can a Tiny Insider Buy at Conagra Signal the Next Big Bull?
Conagra might not be hot sauce, but it’s finally warming up. A small insider buy, strong institutional backing, and a fat dividend yield could turn this frozen-aisle veteran into a comeback story. Just keep an eye on inflation and margins — both can melt fast.
Tilray of Sunshine: CEO Bought Shares Weeks Ago — and Now Earnings Are Finally Rolling In
Tilray finally posted profits and a healthy cash flow — and insiders bought in early. Could this be the long-awaited turnaround, or just another puff of smoke?
Absci: When AI Meets Antibodies — and Insiders Can’t Resist Buying More!
AI is designing drugs, and Absci is leading the charge — with insider confidence, top-tier partners, and a cash runway through 2028. Still pre-revenue but packed with promise, this biotech might just be the next NVIDIA of antibodies.
Directors' Thirst for Shares of Global Water Resources Seems Unquenchable. Should You Binge on Them?
Insiders are gulping up shares of Global Water Resources, betting big on Arizona’s thirst for growth. But while the company’s outlook is steady, its valuation might leave you parched. Sip wisely. 💧📈
CarMax (KMX): Where Insiders Keep Buying — And Cars Keep Driving Off (Mostly the Lot)
Insiders and institutions are revving up for CarMax’s comeback — even as used car sales slow and margins tighten. With shares 70% below their peak and a major digital overhaul underway, this could be the turnaround ride of the year. 🚘📉 Or just another trip to the mechanic.